Besponsa® Clinical Papers
Use the links below to access Besponsa® clinical papers
1. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukaemia; Kantarjian HM et al. NEJM 2016; 375: 740-753
This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-INO-GBR-0370. March 2020
2. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review; Kebriaei P, et al. Bone Marrow Transplant 2018;53:449–456
This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-INO-GBR-0369. March 2020
3. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment; Marks DI et al. Cancer Medicine. 2019;8 :5959-5968.
This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-INO-GBR-0365. March 2020
PP-INO-GBR-0290. May 2020